NCT06572267RecruitingPhase 2
Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease
Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease: a Single-center, Placebo-controlled, Exploratory, Phase 2, Pilot Trial
Source: ClinicalTrials.gov · Last updated 23 Jan 2026
Brief summary (registry, in English)
The development of coronary atherosclerosis is closely related to inflammation, and CD147 may play an important role in its process. The present study was designed to evaluate the effects of long-term administration of mepolizumab (humanized anti-CD147 antibody) on lipid deposition and inflammation in coronary atherosclerotic plaques in patients with high-risk coronary artery disease, and to preliminarily explore the efficacy, safety, and dosage of long-term administration of mepolizumab in this population.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- First submitted
- 22 Aug 2024
- Start date
- 16 Oct 2024
- Primary completion date
- 1 Sept 2026
- Lead sponsor
- Xijing Hospital
- Diseases
- Coronary artery disease
- NCT number
- NCT06572267
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 18
- From 16 Oct 2024 to the primary completion date, 1 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential according to local practice)
- Concurrent medical condition with a life expectancy of less than 3 years
- Known contraindications to medications such as test drug and its components, heparin, or contrast
Other illness
- Suffering from severe systemic diseases, tumors, immune system disorders, infections, malignancy, which in the opinion of the investigator make participation in this study inappropriate
Lab values
- The following criteria are met for any of the laboratory test indicators at the time of screening ①ALT/AST \>3ULN；②TBil ≥2ULN；③WBC\>2ULN；④NEUT\<0.5×109 /L；⑤PLT\<30×109 /L；⑥eGFR \&lt;60 mL/min/1.73 m2（CKD-EPI formula）
Age
- Under the age of 18
Other
- Unable to give informed consent or currently participating in another trial and not yet at its primary endpoint
- Haemodynamical unstable
Who the study is looking for
- Patients with chronic coronary syndrome
- Non-target lesions with stenosis ≥50% by visual assessment
- Angina symptoms manageable via antianginal medication
- High attenuation coefficient (≥-70.1 HU) of perivascular adipose tissue (PVAT) around non-target lesions as assessed by coronary CT angiography (CCTA)
- Patients who are able to complete the follow-up and compliant to the prescribed medication
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ling Tao Coordinator of this site? Confirm its status | Xi'an | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.